BIOLASE, Inc. (NASDAQ:BIOL) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Todd Kehrli - Investor Relations John Beaver - President and Chief Executive Officer Jennifer Bright - Chief Financial Officer Conference Call Participants Kyle Bauser - Lake Street Capital Markets Anthony Vendetti - the Maxim Group Bruce Jackson - The Benchmark Company Operator Good day and welcome to the BIOLASE Third Quarter 2022 Financial Results Conference Call. Please note, this call is being ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading symbol(s) Name of each exchange on which registered Common stock at par value $0.001 per share BIOL The NASDAQ Stock Market LLC (NASDAQ Capital Market) FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transiti ...

BIOLASE, Inc. (OTCQB:BIOL) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Todd Kehrli - EVC Group John Beaver - President, CEO & Director Jennifer Bright - CFO Conference Call Participants Kyle Bauser - Lake Street Capital Markets Anthony Vendetti - Maxim Group Ed Woo - Ascendiant Capital Markets Operator Good day, and welcome to the BIOLASE Second Quarter 2022 Financial Results Conference Call. [Operator Instructions]. Please note, this event is being recorded. I would now ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading symbol(s) Name of each exchange on which registered Common stock at par value $0.001 per share BIOL The NASDAQ Stock Market LLC (NASDAQ Capital Market) FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition pe ...

| --- | --- | --- | --- | --- | |-------|-------|-------------------------------------------------------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | RIOT AS | | | | | | | | | | | | | \| ® | | | | | :: Advancing Dentistry | | | | | | | | | | | | Investor Overview NASDAQ : BIOL \| HIMMAN \| MAY 2022 | | | Safe Harbor Statement Statements made in this presentation and during discussions with BIOLASE representative's that refer to BIOLASE's estimated or anticipated future ...

BIOLASE, Inc. (OTCQB:BIOL) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Todd Kehrli - Investor Relations, EVC Group John Beaver - President and Chief Executive Officer Jennifer Bright - Vice President of Finance Conference Call Participants Bruce Jackson - The Benchmark Company Matt Bullock - Maxim Group Kyle Bauser - Lake Street Operator Good day, and welcome to the BIOLASE First Quarter 2022 Results Conference Call. All participants will be in a listen-only mode. [Operato ...

4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading symbol(s) Name of each exchange on which registered FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: ...

BIOLASE, Inc. (OTCQB:BIOL) Q4 2021 Earnings Conference Call March 17, 2022 4:30 PM ET Company Participants Todd Kehrli - IR, EVC Group John Beaver - President and Chief Executive Officer Jennifer Bright - Vice President, Finance Conference Call Participants Bruce Jackson - Benchmark Company Matthew Bullock - Maxim Group Ed Woo - Ascendiant Capital Disclaimer*: This transcript is designed to be used alongside the freely available audio recording on this page. Timestamps within the transcript are designed to ...

| --- | --- | --- | |-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Safe Harbor Statement Statements made in this presentation and during discussions with BIOLASE representative's that refer to BIOLASE's estimated or anticipated future results or other non-historical facts are forward-looking statements, as are any statements its representatives make concerning BIOLASE's strategic initiatives, anticipated financial performance and product lau ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36385 BIOLASE, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 87-0442441 (State or Other Jurisdiction of Incorpor ...